This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Henry Schein (HSIC) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of -5.71% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to Henry Schein (HSIC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Henry Schein (HSIC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits?
by Zacks Equity Research
Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.
Henry Schein (HSIC) Sales Hurt by Cyber Attack, Macro Woes
by Zacks Equity Research
Henry Schein's (HSIC) financial operations are being affected by the current macroeconomic environment.
Henry Schein (HSIC) Enters Orthopedic Market With New Buyout
by Zacks Equity Research
Henry Schein's (HSIC) recent deals will position it as a prominent producer and supplier in the orthopedic market's Foot and Ankle, Hand and Wrist extremity sectors.
Henry Schein (HSIC) Up 4.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal
by Zacks Equity Research
Henry Schein's (HSIC) dental laboratory business, Zahn Dental, is set to exclusively distribute Myerson's New Trusana 3D Premium Denture System.
Henry Schein (HSIC) Q3 Revenues Miss, 2023 Guidance Cut
by Zacks Equity Research
Henry Schein's (HSIC) third-quarter 2023 performance demonstrates remarkable sales growth in the Technology and Value-Added Service businesses.
Compared to Estimates, Henry Schein (HSIC) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Henry Schein (HSIC) Matches Q3 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 0% and 0.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Henry Schein (HSIC) Q3: Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Henry Schein (HSIC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.
Cardinal Health (CAH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 23.57% and 0.43%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) Set to Post Q3 Earnings: What Awaits?
by Zacks Equity Research
Henry Schein's (HSIC) third-quarter 2023 results are likely to reflect the strong fundamentals of the Dental business.
Henry Schein (HSIC) Acquires Majority Stake in Shield Healthcare
by Zacks Equity Research
Henry Schein (HSIC) completes the majority investment in Shield Healthcare, Inc.
Should Value Investors Buy Henry Schein (HSIC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HSIC vs. MMSI: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
4 Stocks to Buy From the Prospering Dental Supplies Industry
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), backed by the strength of the dental business and acquisitions.
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Henry Schein (HSIC) Gains From Strong Global Network Amid FX Woes
by Zacks Equity Research
Henry Schein's (HSIC) dental software business is progressing well despite a challenging business environment.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.